BioCentury | Feb 7, 2011
Clinical News
AS1411: Phase IIb discontinued
...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....